U.S. markets closed
  • S&P Futures

    4,161.75
    -0.75 (-0.02%)
     
  • Dow Futures

    33,917.00
    -6.00 (-0.02%)
     
  • Nasdaq Futures

    14,009.25
    -4.75 (-0.03%)
     
  • Russell 2000 Futures

    2,254.60
    -1.10 (-0.05%)
     
  • Crude Oil

    63.28
    -0.18 (-0.28%)
     
  • Gold

    1,766.40
    -0.40 (-0.02%)
     
  • Silver

    25.93
    -0.03 (-0.13%)
     
  • EUR/USD

    1.1979
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.5300
    -0.1080 (-6.59%)
     
  • Vix

    16.57
    -0.42 (-2.47%)
     
  • GBP/USD

    1.3780
    -0.0004 (-0.03%)
     
  • USD/JPY

    108.6220
    -0.0940 (-0.09%)
     
  • BTC-USD

    63,208.28
    +263.60 (+0.42%)
     
  • CMC Crypto 200

    1,396.93
    +15.98 (+1.16%)
     
  • FTSE 100

    6,983.50
    +43.92 (+0.63%)
     
  • Nikkei 225

    29,642.69
    0.00 (0.00%)
     

Recap: Antares Pharma Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Antares Pharma (NASDAQ:ATRS) were unchanged after the company reported Q4 results.

Quarterly Results

Earnings per share were flat 0.00% over the past year to $0.03, which were in line with the estimate of $0.03.

Revenue of $44,133,000 up by 16.63% from the same period last year, which beat the estimate of $40,750,000.

Outlook

The upcoming fiscal year's revenue expected to be between $175,000,000 and $200,000,000.

Conference Call Details

Date: Mar 02, 2021

View more earnings on ATRS

Time: 08:30 AM

ET Webcast URL: https://streaming.webcasts.com/starthere.jsp?ei=1424766&tp_key=38c62cb12a

Technicals

Company's 52-week high was at $5.07

52-week low: $1.60

Price action over last quarter: Up 57.89%

Company Description

Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.